Molecular detection of a common mutation in coagulation factor v causing thrombosis via hereditary resistance to activated protein c

Xiao Yuan Liu, Diana Nelson, Chris Grant, Virginia Morthland, Scott H. Goodnight, Richard Press

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

More than half of all patients with familial or recurring venous thrombosis have hereditary resistance to activated protein C (HRAPC) as the result of a specific mis- sense mutation in the gene for coagulation factor V Because the mutant factor Va (with an Arg to Gin substitution at codon 506) cannot be cleaved and inactivated by activated protein C. carriers of this mutation are at significantly increased risk of venous thrombosis. We have recently introduced a direct polymerase chain reaction (PCR)-based clinical diagnostic test for the factor V codon 506 mutation based on the destruction of an Mnl I restriction site by the causative nucleotide substitution. To assess the accuracy of this PCR-based assay, we compared a functional clotting time test for HRAPC with the direct mutation test. Of 47 patients dually tested, only five had discrepant values for the functional test versus the DNA test. Either of these two complementary assays is useful for the accurate diagnosis of HRAPC. The DNA- based test is, however, specifically recommended for evaluation of anticoagulated patients or patients with borderline functional tests and confirmation of genotype in HRAPC families. In an additional analysis of 287 normal individuals, we found an extremely high prevalence of the mutated codon 506 allele—-4% in each of two different populations. The absence of disease in the majority of heterozygous carriers suggests that symptomatic thrombosis requires the simultaneous presence of both a mutated factor V protein and additional synergistic factors.

Original languageEnglish (US)
Pages (from-to)191-197
Number of pages7
JournalDiagnostic Molecular Pathology
Volume4
Issue number3
StatePublished - 1995

Fingerprint

Blood Coagulation Factors
Factor V
Thrombosis
Codon
Mutation
Venous Thrombosis
Proteins
Factor Va
Polymerase Chain Reaction
DNA
Protein C
Routine Diagnostic Tests
Nucleotides
Alleles
Genotype
Thrombophilia due to Activated Protein C Resistance
Population
Genes

Keywords

  • Activated protein C resistance
  • Factor V
  • Mutation
  • Polymerase chain reaction
  • Protein C
  • Thrombosis

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Pathology and Forensic Medicine

Cite this

Molecular detection of a common mutation in coagulation factor v causing thrombosis via hereditary resistance to activated protein c. / Liu, Xiao Yuan; Nelson, Diana; Grant, Chris; Morthland, Virginia; Goodnight, Scott H.; Press, Richard.

In: Diagnostic Molecular Pathology, Vol. 4, No. 3, 1995, p. 191-197.

Research output: Contribution to journalArticle

Liu, Xiao Yuan ; Nelson, Diana ; Grant, Chris ; Morthland, Virginia ; Goodnight, Scott H. ; Press, Richard. / Molecular detection of a common mutation in coagulation factor v causing thrombosis via hereditary resistance to activated protein c. In: Diagnostic Molecular Pathology. 1995 ; Vol. 4, No. 3. pp. 191-197.
@article{75045bf245174b52a82c66badf6d2e45,
title = "Molecular detection of a common mutation in coagulation factor v causing thrombosis via hereditary resistance to activated protein c",
abstract = "More than half of all patients with familial or recurring venous thrombosis have hereditary resistance to activated protein C (HRAPC) as the result of a specific mis- sense mutation in the gene for coagulation factor V Because the mutant factor Va (with an Arg to Gin substitution at codon 506) cannot be cleaved and inactivated by activated protein C. carriers of this mutation are at significantly increased risk of venous thrombosis. We have recently introduced a direct polymerase chain reaction (PCR)-based clinical diagnostic test for the factor V codon 506 mutation based on the destruction of an Mnl I restriction site by the causative nucleotide substitution. To assess the accuracy of this PCR-based assay, we compared a functional clotting time test for HRAPC with the direct mutation test. Of 47 patients dually tested, only five had discrepant values for the functional test versus the DNA test. Either of these two complementary assays is useful for the accurate diagnosis of HRAPC. The DNA- based test is, however, specifically recommended for evaluation of anticoagulated patients or patients with borderline functional tests and confirmation of genotype in HRAPC families. In an additional analysis of 287 normal individuals, we found an extremely high prevalence of the mutated codon 506 allele—-4{\%} in each of two different populations. The absence of disease in the majority of heterozygous carriers suggests that symptomatic thrombosis requires the simultaneous presence of both a mutated factor V protein and additional synergistic factors.",
keywords = "Activated protein C resistance, Factor V, Mutation, Polymerase chain reaction, Protein C, Thrombosis",
author = "Liu, {Xiao Yuan} and Diana Nelson and Chris Grant and Virginia Morthland and Goodnight, {Scott H.} and Richard Press",
year = "1995",
language = "English (US)",
volume = "4",
pages = "191--197",
journal = "Diagnostic Molecular Pathology",
issn = "1052-9551",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Molecular detection of a common mutation in coagulation factor v causing thrombosis via hereditary resistance to activated protein c

AU - Liu, Xiao Yuan

AU - Nelson, Diana

AU - Grant, Chris

AU - Morthland, Virginia

AU - Goodnight, Scott H.

AU - Press, Richard

PY - 1995

Y1 - 1995

N2 - More than half of all patients with familial or recurring venous thrombosis have hereditary resistance to activated protein C (HRAPC) as the result of a specific mis- sense mutation in the gene for coagulation factor V Because the mutant factor Va (with an Arg to Gin substitution at codon 506) cannot be cleaved and inactivated by activated protein C. carriers of this mutation are at significantly increased risk of venous thrombosis. We have recently introduced a direct polymerase chain reaction (PCR)-based clinical diagnostic test for the factor V codon 506 mutation based on the destruction of an Mnl I restriction site by the causative nucleotide substitution. To assess the accuracy of this PCR-based assay, we compared a functional clotting time test for HRAPC with the direct mutation test. Of 47 patients dually tested, only five had discrepant values for the functional test versus the DNA test. Either of these two complementary assays is useful for the accurate diagnosis of HRAPC. The DNA- based test is, however, specifically recommended for evaluation of anticoagulated patients or patients with borderline functional tests and confirmation of genotype in HRAPC families. In an additional analysis of 287 normal individuals, we found an extremely high prevalence of the mutated codon 506 allele—-4% in each of two different populations. The absence of disease in the majority of heterozygous carriers suggests that symptomatic thrombosis requires the simultaneous presence of both a mutated factor V protein and additional synergistic factors.

AB - More than half of all patients with familial or recurring venous thrombosis have hereditary resistance to activated protein C (HRAPC) as the result of a specific mis- sense mutation in the gene for coagulation factor V Because the mutant factor Va (with an Arg to Gin substitution at codon 506) cannot be cleaved and inactivated by activated protein C. carriers of this mutation are at significantly increased risk of venous thrombosis. We have recently introduced a direct polymerase chain reaction (PCR)-based clinical diagnostic test for the factor V codon 506 mutation based on the destruction of an Mnl I restriction site by the causative nucleotide substitution. To assess the accuracy of this PCR-based assay, we compared a functional clotting time test for HRAPC with the direct mutation test. Of 47 patients dually tested, only five had discrepant values for the functional test versus the DNA test. Either of these two complementary assays is useful for the accurate diagnosis of HRAPC. The DNA- based test is, however, specifically recommended for evaluation of anticoagulated patients or patients with borderline functional tests and confirmation of genotype in HRAPC families. In an additional analysis of 287 normal individuals, we found an extremely high prevalence of the mutated codon 506 allele—-4% in each of two different populations. The absence of disease in the majority of heterozygous carriers suggests that symptomatic thrombosis requires the simultaneous presence of both a mutated factor V protein and additional synergistic factors.

KW - Activated protein C resistance

KW - Factor V

KW - Mutation

KW - Polymerase chain reaction

KW - Protein C

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0029116980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029116980&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 191

EP - 197

JO - Diagnostic Molecular Pathology

JF - Diagnostic Molecular Pathology

SN - 1052-9551

IS - 3

ER -